One of the leading companies for ATR, Air Liquide's technology has been selected for Japan's first demo project owned and operated by Inpex Corporation to produce low-carbon hydrogen and ammonia. (Source: Air Liquide)
Autothermal Reforming

Air Liquide Technology Chosen for Japan’s First Production of Low-Carbon H2, Ammonia

Air Liquide’s autothermal reforming technology has been chosen by Inpex Corporation for Japan’s first demonstration project which aims to produce low-carbon hydrogen and ammonia. Once combined with carbon capture technology, autothermal reforming can achieve higher energy efficiency, lower investments and a production process which can assist in capturing up to 99 % of carbon in integrated industrial units.

Read on
Lotte Biologics CEO Richard Won-jik Lee announced the company’s full-fledged entry into the biopharma market as a CDMO at the 2023 JPMorgan Healthcare Conference.  (Source:Lotte Biologics)
Future Vision

Lotte Biologics Intends to Become a Global CDMO

Lotte Biologics has acquired the Syracuse plant in the United States from Bristol Myers Squibb Co. and now plans to expand it by adding ADC contract manufacturing services as well as clinical drug substance incubation and drug product facilities. The firm also plans to invest 3 billion dollars to develop three mega plants in Korea by 2030 with a total production capacity of 360,000 liters of antibody drugs.

Read on